Clinical and biological features in the prognosis of adrenocortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 7, 2006, Pages 2650-2655

  Abiven, Gwenaelle ^a   Coste, Joel ^b   Groussin, Lionel ^a,c   Anract, Philippe ^b   Tissier, Frédérique ^b,c   Legmann, Paul ^b   Dousset, Bertrand ^b   Bertagna, Xavier ^a,c   Bertherat, Jérôme ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Cochin   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; MITOTANE;

ADRENAL CORTEX CARCINOMA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE METASTASIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SEX RATIO; TUMOR VOLUME;

ADRENAL CORTEX NEOPLASMS; ADULT; ANALYSIS OF VARIANCE; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; HYDROCORTISONE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOTANE; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 33745777816     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2730     Document Type: Article

References (33)

1. Libe R, Bertherat J 2005 Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 153:477-487
2. Soreide JA, Brabrand K, Thoresen SO 1992 Adrenal cortical carcinoma in Norway, 1970-1984. World J Surg 16:663- 667; discussion, 668
3. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J 2001 Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 86:117-123
4. Allolio B, Hahner S, Weismann D, Fassnacht M 2004 Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 60:273-287
5. Venkatesh S, Hickey RC, Sellin RV, Fernandez JF, Samaan NA 1989 Adrenal cortical carcinoma. Cancer 64:765-769
6. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, Bonin A, Bricaire H 1990 Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322:1195-1201
7. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C 2001 Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25:891-897
8. Hutter Jr AM, Kayhoe DE 1966 Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med 41:572-580
9. Wooten MD, King DK 1993 Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72:3145-3155
10. Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, Makowska AM 1995 Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 75:2587-2591
11. Causeret S, Monneuse O, Mabrut JY, Berger N, Peix JL 2002 [Adrenocortical carcinoma: prognostic factors for local recurrence and indications for reoperation. A report on a series of 22 patients]. Ann Chir 127:370-377
12. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, Taylor SH, Hess KR, Schultz PN, Samaan NA 1993 Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71:3119-3123
13. Hesketh PJ, McCaffrey RP, Finkel HE, Larmon SS, Griffing GT, Melby JC 1987 Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep 71:222-224
14. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L 1998 Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 83:2194-2200
15. Bukowski RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E, Harker WG 1993 Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 11:161-165
16. Johnson DH, Greco FA 1986 Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 58:2198-2202
17. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D 1984 The treatment of adrenocortical carcinoma with o,p′-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20:47-53
18. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP, Le Bouc Y 2001 Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61:6762-6767
19. Luton JP, Martinez M, Coste J, Bertherat J 2000 Outcome in patients with adrenal incidentaloma selected for surgery: an analysis of 88 cases investigated in a single clinical center. Eur J Endocrinol 143:111-117
20. Bertherat J, Contesse V, Louiset E, Barrande G, Duparc C, Groussin L, Emy P, Bertagna X, Kuhn JM, Vaudry H, Lefebvre H 2005 In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome: identification of two cases of gonadotropin/gastric inhibitory polypeptide-dependent hypercortisolism. J Clin Endocrinol Metab 90:1302-1310
21. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagnere AM, Rene-Corail F, Jullian E, Gicquel C, Bertagna X, Vacher-Lavenu MC, Perret C, Bertherat J 2005 Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 65:7622-7627
22. Sullivan M, Boileau M, Hodges CV 1978 Adrenal cortical carcinoma. J Urol 120:660-665
23. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, Zerbini MC, Liberman B, Carlos Gomes G, Kirschner MA 2000 Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88:711-736
24. Macfarlane DA 1958 Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 23:155-186
25. Hutter Jr AM, Kayhoe DE 1966 Adrenal cortical carcinoma. Results of treatment with o,p′DDD in 138 patients. Am J Med 41:581-592
26. Didolkar MS, Bescher RA, Elias EG, Moore RH 1981 Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients. Cancer 47:2153-2161
27. Favia G, Lumachi F, D'Amico DF 2001 Adrenocortical carcinoma: is prognosis different in nonfunctioning tumors? Results of surgical treatment in 31 patients. World J Surg 25:735-738
28. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L 2005 Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12:657-666
29. King DR, Lack EE 1979 Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases. Cancer 44:239-244
30. Percarpio B, Knowlton AH 1976 Radiation therapy of adrenal cortical carcinoma. Acta Radiol Ther Phys Biol 15:288-292
31. Markoe AM, Serber W, Micaily B, Brady LW 1991 Radiation therapy for adjunctive treatment of adrenal cortical carcinoma. Am J Clin Oncol 14:170-174
32. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, Schlumberger M 2001 Impact of monitoring plasma 1,1- dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385-1392
33. Lindhe O, Skogseid B, Brandt I 2002 Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p′-DDD in human adrenal zona fasciculata/reticularis. J Clin Endocrinol Metab 87:1319-1326